Megadose transplantation of purified peripheral blood CD34+progenitor cells from HLA-mismatched parental donors in children

被引:225
作者
Handgretinger, R
Klingebiel, T
Lang, P
Schumm, M
Neu, S
Geiselhart, A
Bader, P
Schlegel, PG
Greil, J
Stachel, D
Herzog, RJ
Niethammer, D
机构
[1] Univ Tubingen, Dept Pediat Hematol Oncol, Tubingen, Germany
[2] Univ Tubingen, Blood Bank, Tubingen, Germany
[3] Von Haunersches Kinderspital, Munich, Germany
[4] Univ Erlangen Nurnberg, Childrens Univ Hosp, Erlangen, Germany
关键词
mismatch transplantation; CD34-positive selection; donor lymphocyte infusion;
D O I
10.1038/sj.bmt.1702996
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We performed HLA-mismatched stem cell transplantation with megadoses of purified positively selected mobilized peripheral blood CD34(+) progenitor cells (PBPC) from related adult donors in 39 children lacking an otherwise suitable donor. The patients received a mean number of 20.7 +/- 9.8 x 10(6)/kg purified CD34(+) and a mean number of 15.5 +/- 20.4 x 10(3)/kg CD3(+) T lymphocytes. The first seven patients received short term (<4 weeks) GVHD prophylaxis with cyclosporin A, whereas in all the following 32 patients no GVHD prophylaxis was used. In 38 evaluable patients, five patients experienced primary acute GVHD grade I and one patient grade II. In 32 patients, no signs of primary GVHD were seen and GVHD only occurred after T cell add backs. T cell reconstitution was more rapid if the number of transplanted CD34(+) cells exceeded 20 x 10(6)/kg. Of the 39 patients, 15 are alive and well, 13 died due to relapse and 10 transplant-related deaths occurred. We conclude that the HLA barrier can be overcome by transplantation of megadoses of highly purified mismatched CD34(+) stem cells. GVHD can be prevented without pharmacological immunosuppression by the efficient T cell depletion associated with the CD34(+) positive selection procedure. This approach offers a promising therapeutic option for every child without an otherwise suitable donor.
引用
收藏
页码:777 / 783
页数:7
相关论文
共 28 条
[1]  
ANASETTI C, 1995, ANNU REV MED, V46, P169
[2]   BONE-MARROW TRANSPLANTATION [J].
ARMITAGE, JO .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) :827-838
[3]   SUCCESSFUL ENGRAFTMENT OF T-CELL-DEPLETED HAPLOIDENTICAL 3-LOCI INCOMPATIBLE TRANSPLANTS IN LEUKEMIA PATIENTS BY ADDITION OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS TO BONE-MARROW INOCULUM [J].
AVERSA, F ;
TABILIO, A ;
TERENZI, A ;
VELARDI, A ;
FALZETTI, F ;
GIANNONI, C ;
IACUCCI, R ;
ZEI, T ;
MARTELLI, MP ;
GAMBELUNGHE, C ;
ROSSETTI, M ;
CAPUTO, P ;
LATINI, P ;
ARISTEI, C ;
RAYMONDI, C ;
REISNER, Y ;
MARTELLI, MF .
BLOOD, 1994, 84 (11) :3948-3955
[4]   Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].
Aversa, F ;
Tabilio, A ;
Velardi, A ;
Cunningham, I ;
Terenzi, A ;
Falzetti, F ;
Ruggeri, L ;
Barbabietola, G ;
Aristei, C ;
Latini, P ;
Reisner, Y ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193
[5]   Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT [J].
Bader, P ;
Beck, J ;
Frey, A ;
Schlegel, PG ;
Hebarth, H ;
Handgretinger, R ;
Einsele, H ;
Niemeyer, C ;
Benda, N ;
Faul, C ;
Kanz, L ;
Niethammer, D ;
Klingebiel, T .
BONE MARROW TRANSPLANTATION, 1998, 21 (05) :487-495
[6]   IMPACT OF RACIAL GENETIC-POLYMORPHISM ON THE PROBABILITY OF FINDING AN HLA-MATCHED DONOR [J].
BEATTY, PG ;
MORI, M ;
MILFORD, E .
TRANSPLANTATION, 1995, 60 (08) :778-783
[7]   Interleukin 2 in the treatment of acute leukemia [J].
Blaise, D ;
Maraninchi, D .
LEUKEMIA RESEARCH, 1998, 22 (12) :1165-1170
[8]  
Caron PC, 1998, CLIN CANCER RES, V4, P1421
[9]  
GALE RP, 1986, LANCET, V1, P1468
[10]  
GEISELHART A, 1996, NAT IMMUN, V15, P227